Search
for

    Learn

    5 / 801 results

    Research

    5 / 738 results
      Telogen Effluvium: A Non-Scarring, Diffuse Hair Loss Condition

      research Telogen Effluvium

      November 2021 in “CRC Press eBooks”
      Telogen effluvium is a common, temporary hair loss condition often affecting young women.
      The History of Hair Transplantation

      research The History of Hair Transplantation

      3 citations , December 2008 in “The American Journal of Cosmetic Surgery”
      Hair transplantation has evolved to refined techniques like FUE and FUT, with Finasteride and Minoxidil as the only other proven treatments for hair loss.

      research On Telogen Effluvium

      July 2025 in “International Journal of Trichology”
      Telogen effluvium is a common hair loss condition requiring careful diagnosis and treatment.

    Community Join

    5 / 1000+ results

      community cb-03-01 research chem (winlevi/clascoterone cream)

      in Technology  3 upvotes 2 years ago
      The user is considering using CB or clascoterone for hair loss, potentially as an alternative to RU. They're also contemplating asking a dermatologist for topical clascoterone cream to apply to their temple.

      community 2nd HT FOR CROWN AND MID SCALP.

      in Transplants  2 upvotes 6 months ago
      The user underwent a second hair transplant for the crown and mid-scalp, achieving good density. They are using minoxidil, finasteride, and biotin, and considering PRP treatments to enhance growth.

      community bpc-157 scalp injections. 3 months

      in Progress Pictures  52 upvotes 2 months ago
      The user experienced reduced hair shedding after three months of injecting 1mg BPC-157 into the scalp, while continuing to use dutasteride and minoxidil. The injections are painful, and the user sometimes switches to injecting into the buttocks.

      community HLT Megathread on HMI-115 (key takeaways in comments)

      in Research/Science  39 upvotes 3 years ago
      HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.